fatty diacid chain is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
The Portal series is a series of puzzle games developed by Valve which takes place in the same universe as the Half-Life games. The first game, Portal, was released on October 10, 2007, followed by Portal 2 on April 19, 2011. The Half-Life writer, Marc Laidlaw, opposed the crossover with Portal, feeling it "made both universes smaller", and said later: "I just had to react as gracefully as I could to the fact that it was going there without me. It didn't make any sense except from a resource-restricted point of view."
== Function == Obestatin opposes the actions of ghrelin which are growth hormone secretion and increased appetite. The purpose of producing two hormones with opposing effects is not clear: removing the ghrelin gene from mice did not significantly reduce food intake. No secretory convertase is capable of cleaving the recombinant proghrelin precursor by cleavage at the single basic residue required for generation of the obestatin sequence. Thus the physiological generation of this particular peptide sequence remains unproven. Obestatin has opposite action to ghrelin on food intake and plays a role in energy balance. Circuit-resistance exercise resulted in a significant change in GH levels, but had no effect on plasma Obestatin levels.
On the other hand, if the principal plane of the analyzer is along DOC then both the halves will be equally dark. Thus it is clear that if the analyzing Nicol is slightly disturbed from DOC then one half becomes brighter than the other. Hence by using the half shade device, one can measure the angle of rotation more accurately. Determination of specific rotation: In order to determine a specific rotation of an optically active substance (say, sugar), the polarimeter tube is first filled with pure water and the analyzer is adjusted for equal darkness (both the halves should be equally dark) point. The position of the analyzer is noted with the help of the scale. Now the polarimeter tube is filled with a sugar solution of known concentration and again the analyzer is adjusted in such a way that again the equally dark point is achieved. The position of the analyzer is again noted. The difference of the two readings will give the angle of rotation θ. Hence, a specific rotation S is determined as S = θ/LC, where L is the optical path length and C is concentration of the substance.
Sources: en.wikipedia.org
== Construction == Manufacturers have described the cigarette as "a drug administration system for the delivery of nicotine in acceptable and attractive form". Modern commercially manufactured cigarettes consist mainly of a tobacco blend, paper, PVA glue to bond the outer layer of paper together, and often also a cellulose acetate–based filter. While the assembly of cigarettes is straightforward, much focus is given to the creation of each of the components, in particular the tobacco blend. A key ingredient that makes cigarettes more addictive is the inclusion of reconstituted tobacco, which has additives to make nicotine more volatile as the cigarette burns.
Compounds containing one or more elements which can exist in a variety of charge/oxidation states will have a stoichiometry that depends on which oxidation states are present, to ensure overall neutrality. This can be indicated in the name by specifying either the oxidation state of the elements present, or the charge on the ions. Because of the risk of ambiguity in allocating oxidation states, IUPAC prefers direct indication of the ionic charge numbers. These are written as an arabic integer followed by the sign (... , 2−, 1−, 1+, 2+, ...) in parentheses directly after the name of the cation (without a space separating them). For example, FeSO4 is named iron(2+) sulfate (with the 2+ charge on the Fe2+ ions balancing the 2− charge on the sulfate ion), whereas Fe2(SO4)3 is named iron(3+) sulfate (because the two iron ions in each formula unit each have a charge of 3+, to balance the 2− on each of the three sulfate ions). Stock nomenclature, still in common use, writes the oxidation number in Roman numerals (... , −II, −I, 0, I, II, ...). So the examples given above would be named iron(II) sulfate and iron(III) sulfate respectively. For simple ions the ionic charge and the oxidation number are identical, but for polyatomic ions they often differ. For example, the uranyl(2+) ion, UO2+2, has uranium in an oxidation state of +6, so would be called a dioxouranium(VI) ion in Stock nomenclature.
Work by scientists such as Anton Yuryev has contributed to understanding mitochondrial-associated proteins and their interactions. During his postdoctoral research, Yuryev demonstrated that the A-RAF kinase, a signaling protein, can localize to mitochondria, providing insight into how cellular signaling pathways intersect with mitochondrial function. His broader work in molecular biology and bioinformatics has also explored gene regulation, protein interactions, and biological networks, helping to contextualize mitochondrial processes within larger cellular systems.
Annular lichen planus Atrophic lichen planus Bullous lichen planus (vesiculobullous lichen planus) Erosive lichen planus Erythema dyschromicum perstans (ashy dermatosis, dermatosis cinecienta) Giant cell lichenoid dermatitis Hepatitis-associated lichen planus Hypertrophic lichen planus (lichen planus verrucosus) Idiopathic eruptive macular pigmentation Inverse lichen planus Keratosis lichenoides chronica (Nékam's disease) Kraurosis vulvae Lichen nitidus Lichen planus actinicus (actinic lichen nitidus, actinic lichen planus, lichen planus atrophicus annularis, lichen planus subtropicus, lichen planus tropicus, lichenoid melanodermatitis, lichenoid melanodermatosis, summertime actinic lichenoid eruption) Lichen planus pemphigoides Lichen planus pigmentosus Lichen planus–lichen sclerosus overlap syndrome Lichen ruber moniliformis Lichen sclerosus (lichen sclerosus et atrophicus) Lichen striatus (Blaschko linear acquired inflammatory skin eruption, linear lichenoid dermatosis) Lichen verrucosus et reticularis Lichenoid trikeratosis Lichenoid dermatitis Lichenoid reaction of graft-versus-host disease Linear lichen planus Mucosal lichen planus Peno-gingival syndrome Ulcerative lichen planus Vulvovaginal gingival syndrome Vulvovaginal lichen planus
Sources: en.wikipedia.org
=== Wonder Beyond Belief: On Christianity (2018) === While Kermani's scholarly theses deal with Islamic tradition, he has since repeatedly turned his attention to Christianity. Particularly prominent and noteworthy in this regard is his Wonder Beyond Belief: On Christianity published in German in 2015 and in English in 2018. The book approaches Christianity in an aesthetic way—through thoughtful reflections on images by various Christian artists, especially from the Italian Baroque period. These self-contained, deeply researched art-historical essays open up exciting perspectives on central characteristics of Christianity and have met with great resonance. In a highly original approach to the cross, Kermani's characteristic linking of beauty and the terror of God can be found once again. Attracted by the aesthetic power of artist and sculptor Karl Schlamminger's cross sculpture, but also by the beauty and grace with which the cross is carried in Botticelli's depictions, Kermani is moved by the aesthetic power of the cross. However, he also recognizes the cross as a believer's approach to suffering itself—for example, when he compares the thieves on the cross to mercenaries who crucify agitators in Syria or Iraq today. Indeed, Kermani associates the cross with human victims throughout history, citing Jesus's lamenting accusation on the cross. He insists on not separating Jesus from ourselves and on discovering our own suffering in Jesus's suffering.
== Further reading == Webster, Gregory K.; Kott, L; Maloney, T; et al. (2005). "JALA Tutorial: Considerations When Implementing Automated Methods into GxP Laboratories". Journal of the Association for Laboratory Automation. 10 (3). Elsevier: 182–191. doi:10.1016/j.jala.2005.03.003.
Because of the rapid hydrolysis of the ester, the reaction should be carried out at pH 4.5, in buffered phosphoric acid the product can even be obtained in virtually quantitative yield. The compound can be purified by recrystallization from ethanol or ethyl acetate. Compared with the benzotriazole derivatives 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) (which are widely used as peptide-linking reagents but are explosive), ethyl cyanohydroxyiminoacetate exhibits a markedly slowed thermal decomposition on heating.
== Further reading == Dean L (March 2017). "Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520380.
== Veterinary use == BCG is used in England by licensed individuals to vaccinate wild badgers by trapping and release. It reduces new bovine TB infection rates by up to 76% in vaccinated badgers. It also exhibits a herd immunity effect, where a badger social group with more than one-third vaccination coverage shows up to 79% lower new infection in cubs. There is no evidence that vaccinated badgers excrete live BCG into the environment. Vaccination initiatives have been lead both by the government's Animal and Plant Health Agency and by private individuals and groups such as farmers seeking to protect their livestock and landowners seeking to clear their land of TB. BCG vaccination in cattle has completed a phase II trial in the UK with satisfactory results. The phase III trial started in 2025.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.